{"id":100330,"date":"2024-11-25T13:58:25","date_gmt":"2024-11-25T12:58:25","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/"},"modified":"2024-11-27T17:41:44","modified_gmt":"2024-11-27T16:41:44","slug":"gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/","title":{"rendered":"Gilead acquires investigational assets for the HIV vaccine from AELIX Therapeutics"},"content":{"rendered":"<p><strong><a href=\"https:\/\/www.pcb.ub.edu\/en\/empresa\/aelix-therapeutics\/\" target=\"_blank\" rel=\"noopener\">Aelix Therapeutics<\/a>, a\u00a0spin off\u00a0company from\u00a0<a href=\"https:\/\/www.irsicaixa.es\/en\" target=\"_blank\" rel=\"noopener\">IrsiCaixa<\/a>, based in the Barcelona Science Park and specializing in the discovery and development of immunotherapies to treat HIV infection, announced today the acquisition of its investigational assets related to the HTI therapeutic HIV vaccine by Gilead Sciences. The HTI immunogen has the potential to become the first immunotherapy to produce a \u2018functional cure\u2019 for HIV infection.\u00a0<\/strong><\/p>\n<p>The HTI immunogen, which forms the foundation of this therapeutic vaccine, was designed at IrsiCaixa by researchers\u00a0<strong>Christian Brander<\/strong>, <strong>Beatriz Mothe<\/strong>\u00a0and\u00a0<strong>Anuska Llano<\/strong> as part of the HIVACAT program and the support of the Fundaci\u00f3 Gl\u00f2ria Soler. Subsequently, Aelix clinically developed it, achieving promising results in phase 1 and phase 2 clinical trials.<\/p>\n<p>The HTI immunogen was designed to redirect the immune response toward the most vulnerable regions of HIV, a strategic approach aimed at overcoming the limitations of current therapies.<\/p>\n<p>According to<strong> Christian Brander<\/strong>, ICREA researcher at IrsiCaixa and CEO and co-founder of Aelix: \u201cWe are excited that our HTI T-cell immunogen is now in the hands of an innovative pharmaceutical company like Gilead Sciences, which has the tools and capabilities to further evaluate this asset as part of a potential approach to an HIV cure strategy.\u201d<\/p>\n<p><strong>Thomas Hecht<\/strong>, executive chairman of Aelix, highlights that this agreement will enable further progress toward the development of a transformative strategy against HIV. \u201cWe are excited that such a prominent company as Gilead, a leader in HIV treatment, prevention and cure research, has decided to acquire AELIX\u2019s HTI therapeutic HIV vaccine investigational assets. The HTI vaccines have shown promising results in phase 1 and phase 2 clinical trials, and we are eager to see this immunogen move forward through this acquisition and potentially become an important aspect of the search for an HIV cure. We are thankful to our early-stage investors including Ysios Capital, which had the vision to support the development of potential HIV cure strategies.\u201d<\/p>\n<p>\u00bb<strong>\u00a0More information:<\/strong>\u00a0<a href=\"https:\/\/www.aelixtherapeutics.com\/\" target=\"_blank\" rel=\"noopener\">Aelix Therapeutics website [+]<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Aelix Therapeutics, a\u00a0spin off\u00a0company from\u00a0IrsiCaixa, based in the Barcelona Science Park and specializing in the discovery and development of immunotherapies to treat HIV infection, announced today the acquisition of its&#8230;<\/p>\n","protected":false},"author":14,"featured_media":100235,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[36],"tags":[],"class_list":["post-100330","post","type-post","status-publish","format-standard","has-post-thumbnail","category-science"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gilead acquires investigational assets for the HIV vaccine from AELIX Therapeutics - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gilead acquires investigational assets for the HIV vaccine from AELIX Therapeutics - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"Aelix Therapeutics, a\u00a0spin off\u00a0company from\u00a0IrsiCaixa, based in the Barcelona Science Park and specializing in the discovery and development of immunotherapies to treat HIV infection, announced today the acquisition of its...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-25T12:58:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-27T16:41:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/11\/BeaAnuskaChristian_Aelix.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1238\" \/>\n\t<meta property=\"og:image:height\" content=\"454\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"Gilead acquires investigational assets for the HIV vaccine from AELIX Therapeutics\",\"datePublished\":\"2024-11-25T12:58:25+00:00\",\"dateModified\":\"2024-11-27T16:41:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\\\/\"},\"wordCount\":334,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/BeaAnuskaChristian_Aelix.png\",\"articleSection\":[\"SCIENCE\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\\\/\",\"name\":\"Gilead acquires investigational assets for the HIV vaccine from AELIX Therapeutics - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/BeaAnuskaChristian_Aelix.png\",\"datePublished\":\"2024-11-25T12:58:25+00:00\",\"dateModified\":\"2024-11-27T16:41:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/BeaAnuskaChristian_Aelix.png\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/BeaAnuskaChristian_Aelix.png\",\"width\":1238,\"height\":454},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gilead acquires investigational assets for the HIV vaccine from AELIX Therapeutics\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/en\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gilead acquires investigational assets for the HIV vaccine from AELIX Therapeutics - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/","og_locale":"en_US","og_type":"article","og_title":"Gilead acquires investigational assets for the HIV vaccine from AELIX Therapeutics - Parc Cient\u00edfic de Barcelona","og_description":"Aelix Therapeutics, a\u00a0spin off\u00a0company from\u00a0IrsiCaixa, based in the Barcelona Science Park and specializing in the discovery and development of immunotherapies to treat HIV infection, announced today the acquisition of its...","og_url":"https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2024-11-25T12:58:25+00:00","article_modified_time":"2024-11-27T16:41:44+00:00","og_image":[{"width":1238,"height":454,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/11\/BeaAnuskaChristian_Aelix.png","type":"image\/png"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Paula Ca\u00f1al","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"Gilead acquires investigational assets for the HIV vaccine from AELIX Therapeutics","datePublished":"2024-11-25T12:58:25+00:00","dateModified":"2024-11-27T16:41:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/"},"wordCount":334,"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/11\/BeaAnuskaChristian_Aelix.png","articleSection":["SCIENCE"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/","url":"https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/","name":"Gilead acquires investigational assets for the HIV vaccine from AELIX Therapeutics - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/11\/BeaAnuskaChristian_Aelix.png","datePublished":"2024-11-25T12:58:25+00:00","dateModified":"2024-11-27T16:41:44+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/11\/BeaAnuskaChristian_Aelix.png","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2024\/11\/BeaAnuskaChristian_Aelix.png","width":1238,"height":454},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/en\/gilead-acquires-investigational-assets-for-the-hiv-vaccine-from-aelix-therapeutics\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/en\/"},{"@type":"ListItem","position":2,"name":"Gilead acquires investigational assets for the HIV vaccine from AELIX Therapeutics"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/en\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/100330","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/comments?post=100330"}],"version-history":[{"count":5,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/100330\/revisions"}],"predecessor-version":[{"id":100338,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/posts\/100330\/revisions\/100338"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media\/100235"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/media?parent=100330"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/categories?post=100330"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/en\/wp-json\/wp\/v2\/tags?post=100330"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}